Compare TTD & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTD | RDY |
|---|---|---|
| Founded | 2009 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 11.6B |
| IPO Year | 2016 | 2001 |
| Metric | TTD | RDY |
|---|---|---|
| Price | $22.43 | $13.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 34 | 1 |
| Target Price | ★ $46.22 | $16.90 |
| AVG Volume (30 Days) | ★ 14.2M | 2.5M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $2,896,284,000.00 | N/A |
| Revenue This Year | $13.94 | $7.72 |
| Revenue Next Year | $12.61 | $3.50 |
| P/E Ratio | $26.64 | ★ $18.67 |
| Revenue Growth | ★ 18.47 | N/A |
| 52 Week Low | $19.74 | $12.77 |
| 52 Week High | $91.45 | $16.17 |
| Indicator | TTD | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 44.81 |
| Support Level | $21.41 | $12.90 |
| Resistance Level | $24.59 | $14.21 |
| Average True Range (ATR) | 1.05 | 0.26 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 42.58 | 31.82 |
The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on devices like computers, smartphones, and connected TVs. It uses data in an iterative manner to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry, and it generates revenue from fees based on a percentage of what its clients spend on advertising.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.